Becon Les Granits

Researchers are evaluating the effects of the probiotic B. lactis B94 on infants diagnosed with infantile colic. This randomized, double-blind, placebo-controlled Phase 2 study aims to determine whether the probiotic can reduce the duration of daily crying compared to a placebo after 4 weeks of treatment. Infantile colic is characterized by prolonged periods of crying or fussiness, and this study seeks to explore a potential dietary intervention to ease these symptoms. Participants will be randomly assigned to one of two groups: one receiving a daily sachet of the probiotic B. lactis B94, and the other receiving a placebo. Both treatments are taken once daily, dissolved in 10 ml of lukewarm water, and administered at approximately the same time each day. The study spans 6 weeks, including a 1-week baseline period, a 4-week intervention period, and a 1-week follow-up. During this time, families will attend three in-person visits and participate in four phone calls to support adherence and monitoring. Throughout the study, parents will maintain questionnaires, records, and diaries related to their infant's symptoms. Researchers will track changes in daily crying duration as the primary outcome over 4 weeks. The study also involves clinical assessments during visits and telephone follow-ups to ensure safety and collect data. Participation requires exclusive breastfeeding and commitment to study procedures over the full 6-week period.

Researchers are evaluating two blood tests, eLIFT and FibroMeter, to screen for advanced liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and/or alcoholic liver disease (ALD) in primary care settings. These chronic liver diseases are common and can lead to serious complications if advanced fibrosis is not detected early. General practitioners often find it challenging to identify patients with advanced fibrosis because routine exams and tests may appear normal. The study compares the eLIFT test, designed for easy use by general practitioners with simple calculation, to the more specialized FibroMeter test. Both tests are blood-based and aim to detect advanced liver fibrosis. Patients may also undergo elastography, a device-based liver stiffness measurement, or liver biopsy if needed. The study is conducted in primary care centers where patients with NAFLD and/or ALD will be screened using these tests. Participants provide blood samples and undergo clinical evaluations during the study. Researchers will measure how sensitive each test is in detecting advanced liver fibrosis. The study includes collecting blood samples at local laboratories and monitoring outcomes such as test sensitivity on the same day. The total participation timeframe includes initial screening and diagnostic testing procedures within one day.